Phase 2 COPD Trial, Recruiting NCT05951777 Sponsor: Hope Biosciences LLC Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT05951777
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged between 18 and 55 years old
  • People who have documented brain or nervous system damage caused by a closed head injury (a head injury that did not break the skull), where current standard treatments are unlikely to help further
  • People whose level of recovery falls within a specific range on a medical scale called the Glasgow Outcome Scale-Extended, meaning they have some ongoing difficulties but are not in the most severely affected category (confirm with trial site)
  • People whose injury or diagnosis occurred more than 6 months ago but no more than 20 years ago
  • People who are able to give consent themselves, or who have a legally authorised representative who can give consent on their behalf
  • People who are able to communicate verbally in English or Spanish

Who may not be able to join:

  • People with a known intellectual disability, or uncontrolled mental health conditions that could affect the ability to measure changes in thinking or behaviour
  • People who have had a recent infection that has been treated
  • People with kidney disease or reduced kidney function, based on a blood test result
  • People with liver disease or reduced liver function, based on blood test results
  • People with a history of cancer
  • People with a weakened immune system, based on a blood test result
  • People who test positive for HIV, Hepatitis B, Hepatitis C, or Syphilis
  • People with alcohol or chemical dependency that, in the opinion of the lead researcher, would prevent safe participation
  • People with acute or ongoing lung disease that requires significant medication or oxygen support
  • People with bleeding disorders, including a specific immune-related blood clotting condition called heparin-induced thrombocytopenia
  • People with a known sensitivity or allergy to heparin, Lovenox, or pork products
  • People who have a mechanical prosthetic heart valve
  • People who have previously received a stem cell treatment, gene therapy, or cellular therapy
  • People whose brain scan (CT or MRI) shows no abnormalities
  • People with a history of spinal cord injury
  • People diagnosed with a genetic or metabolic disorder linked to their neurological condition
  • People with other medical conditions that, in the opinion of the researcher, could increase the risks of taking part
  • Women of childbearing potential who test positive for pregnancy at the screening visit, or anyone (male or female) who is unwilling to use an acceptable form of birth control during the trial
  • People who are currently taking part in another clinical trial involving a drug or medical device
  • People who are unable or unwilling to undergo the required brain scans (PET scan and a specific type of MRI) or to cooperate with the assessments
  • People who have metal implants in their body — including baclofen pumps — that would make the specialised MRI scan unsafe or impossible
  • People who are unwilling or unable to return for the required follow-up visits

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Charles S Cox, MD, The University of Texas Health Science Center, Houston

Phone: 713-500-7395

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hope Biosciences LLC
Registry
ClinicalTrials.gov
Start date
16 April 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Glucose; Calcium; Albumin; Total Protein; Sodium; Total carbon dioxide; Potassium; Chloride; BUN (blood urea nitrogen); Creatinine; Alkaline phosphatase; Alanine aminotransferase; Aspartate aminotransferase; Total Bilirubin; White blood cell; Red blood cell; Hemoglobin; Hematocrit; Mean corpuscular volume; Mean corpuscular hemoglobin; Mean corpuscular hemoglobin concentration; Red cell distribution width; Neutrophils; Lymphocytes; Monocytes; Eosinophils; Basophils; Absolute Neutrophils; Absolute lymphocytes; Absolute monocytes; Absolute eosinophils; Absolute basophils; Immature Granulocytes; A...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov